HOME >> BIOLOGY >> NEWS
Cyrospace, University of Houston sign commercialization agreement

HOUSTON, Oct. 21, 2003 Cyrospace Inc. and the University of Houston have signed a commercialization agreement in which the company will license and commercialize inventions and technologies created by the faculty, staff and students of the university.

According to this agreement, which was announced Sept. 29, Cyrospace will assist UH in realizing the commercial potential of its advanced technologies in the marketplace.

"This agreement is another step in enhancing Cyrospace's portfolio of innovative technologies required to meet the technology challenges of our customers," said Michael Cyrus, Cyrospace's president and CEO. "This relationship will produce revenues for both the university and Cyrospace, enabling UH to concentrate on research and development while allowing them to benefit from our expertise in technology commercialization."

Arthur Vailas, UH vice president for research and intellectual property management, also praised the agreement, saying, "Our principal goal is to foster research and scholarship. The effective transfer of university-wide technology to industry contributes to that goal. Cyrospace has developed strong commercial alliances with world-renowned innovators, as well as educational and research institutions. University of Houston joins a select group of organizations benefiting from experience and expertise that Cyrospace contributes to such relationships."


'"/>

Contact: Lisa Merkl
lkmerkl@uh.edu
713-743-8192
University of Houston
21-Oct-2003


Page: 1

Related biology news :

1. Indiana University, EPA to study airborne PCBs
2. University of Alberta researcher looks for clues to mysterious disease
3. Northeastern University receives $12.4 million NSF grant for creation of nanomanufacturing institute
4. Washington University in St. Louis leads group studying aging process
5. Tufts University establishes $4 million dollar tissue engineering resource center
6. Case for IBD combination therapy comes from research at Baylor, MIT and Hebrew University
7. As informatics grows, Indiana University helps set research agenda
8. University of Arizona licenses patent for natural fungicide
9. Washington University in St. Louis plays key role in sequencing moss genome
10. University of Pittsburgh receives $10 million grant for head and neck cancer
11. Clemson University spin-off uses corn to make plastics, provide cleaner air

Post Your Comments:
(Date:12/5/2014)... MOUNTAIN VIEW, Calif. , Dec. 4, 2014 ... and safety has boosted investments in new testing ... products has also given rise to a range ... driven by the requirements of Generation Y, which ... digital technologies. As a result, product development strategies ...
(Date:12/4/2014)... Dec. 3, 2014  Crossmatch™, a leading provider ... its DigitalPersona ® Pro Enterprise software and ... deployed throughout First Bank branch locations in ... Carolina and Virginia. First Bank, a progressive ... Pines, North Carolina , selected the Crossmatch ...
(Date:12/3/2014)... , Dec. 2, 2014 As part ... readers, Inception Technologies is pleased to announce the release ... for customers to collect the workforce data that they ... that have been left by existing readers. Many such ... interface, connectivity and modern technology. Older models force users ...
Breaking Biology News(10 mins):Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3Inception Technologies to Release New Biometric Reader 2
(Date:12/19/2014)... December 18, 2014 With only 2 ... special on Sartorius Biohit products . The product ... pipettes, Picus Electronic Pipette Trade-in Program, and free pipette ... Safety officers around the world. They are ideal for ... features include:, ,     Full volume range of ...
(Date:12/19/2014)... , Dec. 18, 2014   ISN has ... Safety Performance Indicators publication series. With data ... activity reported in 2013 within its online contractor management ... safety key performance indicator (KPI) statistics. ... U.S. publication is available in two industry ...
(Date:12/17/2014)... Based on the revenues gained ... market is dominated by four major players contributing ... These players include GE Healthcare (U.K.), Siemens AG ... , Full Report Copy at http://www.marketsandmarkets.com/Market-Reports/surgical-imaging-market-210534462.html ... be attributed to its strong product portfolio, which ...
(Date:12/17/2014)... 17, 2014 Ipsen Biopharmaceuticals, Inc., ... ADR: IPSEY), today announced that Somatuline® ... Somatuline®) was approved by the U.S. Food and ... neuroendocrine tumors (GEP-NETs) in adult patients with unresectable, ... disease to improve progression-free survival (PFS). , “The ...
Breaking Biology Technology:Major Pipette Distributor Pipette.com Announces Sartorius Year End Specials 2ISN Releases Third Edition of US Contractor Health & Safety Performance Indicators Publication Series 2ISN Releases Third Edition of US Contractor Health & Safety Performance Indicators Publication Series 3Global Refurbished Surgical Imaging Market by Product & Application is Estimated to Reach $1.25 Billion by 2019 - New Research Report by MarketsandMarkets 2Global Refurbished Surgical Imaging Market by Product & Application is Estimated to Reach $1.25 Billion by 2019 - New Research Report by MarketsandMarkets 3Global Refurbished Surgical Imaging Market by Product & Application is Estimated to Reach $1.25 Billion by 2019 - New Research Report by MarketsandMarkets 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 5Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 6Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 7Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 8
Cached News: